ERBB3 and cancer: Patritumab deruxtecan is an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker for targeted delivery of cytotoxic drugs into cancer cells (Lim et al., 2022) (Table 1).